Award Number : W 81 XWH - 09 - 1 - 0154 TITLE : Novel Aptamers To Target Metastasis PRINCIPAL INVESTIGATOR : Evan Keller CONTRACTING ORGANIZATION : Regents of the University of Michigan

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation. Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. Metastasis and tumor progression at metastatic sites ultimately results in the demise of prostate cancer (PCa) patients. Currently there are no highly effective methods that can target these problems. Aptamers, which have proven clinical efficacy for non-neoplastic disease and are generally more specific and stable than antibodies, may have clinical utility in PCa. However, defining aptamers that can prevent metastasis is challenging due to the fact that many proteins that play a role in the metastatic process are unknown. The overall goal of this project is to develop novel method to inhibit cancer metastasis. The major hypothesis to be tested is that aptamers (short oligonucleotides) can be developed that target the process of invasion, without prior knowledge of a target protein, and that these aptamers will inhibit the development of metastasis. We also hypothesize that the aptamers can be used to identify cell surface proteins that are important mediators of metastasis. This latter information is important as it may help identify further therapeutic targets. We have made some initial progress towards i